Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

* Histologic confirmed diagnosis of malignant melanoma

  * Stage IV disease
  * Not amenable tosurgery
* Measurable disease with at least one lesion whose longest diameter canbe measured as ≥ 20 mm by CT or MRI scans OR ≥ 10 mm by spiral CT

  * No disease that is measurable by physical examination only
* No brain metastases per MRI or CT
* No radiographically documented invasion of adjacent organs(duodenum, stomach, etc.) or tumor invading major blood vessels
* ECOG performance status 0-1
* Life expectancy ≥ 4 months
* ANC ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Hemoglobin ≥ 9 g/dL (transfusion allowed)
* Creatinine ≤ 1.5 times upper limit of normal (ULN)
* Total bilirubin ≤ 1.5 mg/dL (unless Gilbert syndrome)
* AST ≤ 2.5 times ULN
* Alkaline phosphatase ≤ 2.5 times ULN
* Urine protein:creatinine ratio \< 1.0 at screening ORproteinuria \< 2+ by urine dipstick or protein ≤ 1 g by 24-hour urine collection
* Negative serum pregnancy test
* Not pregnant or nursing
* Fertile patients must use effective contraception
* Active infection requiring parenteral antibiotics
* Poorly controlled high blood pressure (≥ 150 mm Hg systolic and/or100 mm Hg diastolic) despite treatment
* NYHA class II-IV congestive heart failure
* Serious cardiac arrhythmia requiring medication
* Myocardial infarction or unstable angina within the past 6 months
* Clinically significant peripheral vascular disease
* Deep venous thrombosis or pulmonary embolus within the past year
* Active bleeding or pathological conditions that carry high risk of bleeding (e.g., known esophageal varices)
* Serious, non-healing wound (including wounds healing by secondary intention), ulcer or bone fracture
* Abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within the past 6 months
* History of CNS disease (e.g., primary brain tumor, vascular abnormalities, etc.)
* Clinically significant stroke or TIA within the past 6 months
* Seizures not controlled with standardmedical therapy
* Peripheral neuropathy ≥ grade 2
* History of other malignancy within the past 5 years except basal cell or squamous cell carcinoma of the skin treatable with local resection only or carcinoma in situ of the cervix
* Significant traumatic injury within the past 4 weeks
* History of hypertensive crisis or hypertensive encephalopathy
* Active or recent (≤ 30 days) history of hemoptysis (≥ ½ teaspoon of bright red blood per episode)
* Known hypersensitivity to any of the components of bevacizumab
* Known to be HIV positive
* Current or known history of hepatitis
* Prior adjuvant chemotherapy and/or immunotherapy for this cancer allowed
* No prior treatment with agents disrupting VEGF activity (i.e., bevacizumab,VEGF-trap, anti-VEGFR Mab)
* No ongoing need for full-dose oral or parenteral anticoagulation
* No ongoing anti-platelet treatment other than low-dose aspirin(i.e., aspirin 81 mg daily)
* No other investigational agents within the past 4 weeks
* No major surgical procedure or open biopsy within the past 4 weeks
* No fine needle aspirations or core biopsies within the past 7 days
* No prior chemotherapy in the metastatic setting
* No prior treatment with sunitinib malate or sorafenib
* No prior treatment with any taxane-based chemotherapy
* Patients who have had \> 25% of their functional bone marrow irradiated are not eligible for this trial
* No adjuvant radiation therapy within the past 4 weeks
* More than 2 weeks since prior and no concurrent palliative radiation therapy
* No concurrent major surgical procedure
* No concurrent participation in another clinical study for procedures or agents that treat the same primary study malignancy